AstraZeneca’s Tagrisso secures FDA breakthrough therapy designation for first-line treatment of NSCLC

AstraZeneca has achieved a significant milestone with its lung cancer drug, Tagrisso (osimertinib), which has recently been granted the Breakthrough Therapy Designation (BTD) by the ... Read More